Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 16/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 0.37 |
| ▸ | CTSD | P07339 | 14/20 | 0.37 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493993 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2MLLT3MLLT1 | |
| SCHEMBL2497501 | 0.86 | SMN1; SMN2 (0.38) | SMN1; SMN2MLLT3MLLT1 | |
| SCHEMBL2501420 | 0.85 | SCN9A (0.44) | SMN1; SMN2MLLT3MLLT1 | |
| SCHEMBL2495873 | 0.85 | CTSA (0.40) | — | |
| SCHEMBL2498200 | 0.85 | RPS6KA3 (0.40) | SMN1; SMN2MLLT3MLLT1 | |
| SCHEMBL2501417 | 0.84 | BACE1 (0.37) | BACE1BACE2CTSDMLLT3MLLT1 | |
| SCHEMBL2498293 | 0.83 | FFAR1 (0.43) | MLLT3MLLT1 | |
| SCHEMBL2502844 | 0.83 | HSD17B14 (0.38) | BACE1BACE2CTSDMLLT3MLLT1 | |
| SCHEMBL2497789 | 0.83 | SCN9A (0.51) | — | |
| SCHEMBL2498897 | 0.83 | FFAR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | claimed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | claimed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | claimed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | SMN1; SMN2 2976/4885BACE1 1809/4885BACE2 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.